(28 customer reviews)

Lumigan eyedrops (0.03%) is an ophtalmic solution which helps in treating glaucoma. Glaucoma is a disease which affects the eye and can in time lead to damage of the optical nerve and blindness. Lumigan eye drops are very efficient in lowering the intra ocular pressure, which is a direct consequence of glaucoma. Lumigan eye drops stabilize the natural flow of the liquid that is contained inside the eye, helping with its excretion, thus reducing the risk of blindness.

SKU: Lumigan Category:
Where to buy Lumigan online?


Looking for a drugstore where you can buy Lumigan online? You can click on the button and go to the pharmacy with the best prices. Anonymous delivery, quality medications, absolutely confidentiality. Go to an online pharmacy and select the appropriate Lumigan dosage, and then the required number of tablets. The buying process will be as secure and safe as possible. You can also buy Lumigan with overnight delivery at the pharmacy, the medicine will be delivered tomorrow. The order is made no because we trust you and understand that you already know which medicine you need.

Special instructions

Before starting treatment, patients should be informed about possible eyelash enlargement, increased pigmentation of the eyelash skin and pigmentation of the iris, since these effects have been established during studies of the drug Lumigan. Some changes may be permanent and may be accompanied by differences between the eyes if the instillation of the drug was carried out only in one eye. The increase in iris pigmentation occurs slowly and may be unnoticeable for several months or years. As a result of treatment with Bimatoprost at a dose of 0.1 mg/ml in the form of eye drops for 12 months, only one case of iris hyperpigmentation was noted (frequency 0.5%). It has been reported that pigmentation changes in periorbital tissues are reversible and disappear upon discontinuation of administration. The use of Lumigan in patients with impaired respiratory function has not been studied, and therefore it should be prescribed with caution to this group of patients. In the course of clinical studies in patients with a history of impaired respiratory function, there were no significant adverse effects on respiratory function. The use of Lumigan in patients with heart block or with uncontrolled congestive heart failure has not been investigated. Lumigan should be used with caution in patients prone to low heart rate or low blood pressure. The use of Lumigan in patients with inflammatory eye diseases, neovascular, inflammatory, angle-closure, congenital glaucoma or narrow-angle glaucoma has not been investigated. Lumigan should be used with caution in patients at risk of macular edema (with aphakia, pseudophakia with damage to the posterior capsule of the lens). Lumigan should be used with caution in patients with a history of viral eye infections (for example, herpes simplex) or uveitis / inflammation of the iris. Hair growth is possible in areas of the skin where the drug constantly comes into contact with the skin. It is necessary to apply Lumigan according to the instructions for use and do not allow the drug to get on the skin. There have been reports of bacterial keratitis associated with the use of multi-dose containers for topical ophthalmic products. These containers were accidentally contaminated by patients who, in most cases, had concomitant eye disease. Patients with rupture of the ocular epithelial surface are at greater risk of developing bacterial keratitis. The tip of the dropper bottle should not come into contact with the eye, surrounding surfaces, fingers and other surfaces to avoid microbial contamination of the mouth. Lumigan, 0.1 mg/ml, contains the preservative benzalkonium chloride (200 ppm), which can be absorbed by soft contact lenses. Irritation of the mucous membrane of the eyes and discoloration of soft contact lenses may occur due to the presence of benzalkonium chloride. Contact lenses must be removed before the drug is administered, they can be put on 15 minutes after instillation. Benzalkonium chloride has been reported to cause speckled keratopathy and/or toxic ulcerative keratopathy. Since Lumigan, 0.1 mg/ml, contains benzalkonium chloride, it should be used with caution in patients with dry eye syndrome, with corneal damage and in patients who use several medications containing benzalkonium chloride in the form of eye drops. In addition, it is necessary to monitor the condition of patients with prolonged treatment with the drug. The use of Lumigan in patients with moderate to severe renal or hepatic impairment has not been investigated. Therefore, caution should be exercised when treating patients of this group. In patients with a history of moderate hepatic impairment or abnormal indicators of AlAT, AsAT and/or bilirubin, the use of bimatoprost in the form of eye drops led to the development of side effects from the liver for 24 months. The use of more than 1 dose of bimatoprost per day leads to a decrease in the severity of the effect of reducing increased intraocular pressure in patients with glaucoma or in patients with increased intraocular pressure. Patients who use Lumigan with other prostaglandin analogues should be under the supervision of a doctor and check intraocular pressure. If more than one local ophthalmic drug is used, it is necessary to take a 5-minute break between each instillation. The ability to influence the reaction speed when driving vehicles or working with other mechanisms. Lumigan has little effect on the reaction speed when driving vehicles or working with other mechanisms. As with other eye drops, if temporary blurred vision occurs after instillation, the patient must wait until vision is restored before driving vehicles or working with other mechanisms. Use during pregnancy or lactation. There is no adequate data regarding the use of bimatoprost in pregnant women. Animal studies have demonstrated reproductive toxicity to the female when using the drug in high doses. Lumigan should be used during pregnancy only if absolutely necessary, when the expected benefit to the mother exceeds the potential risk to the fetus. It is unknown whether bimatoprost penetrates into breast milk. The decision to prolong/discontinue breastfeeding or continue/discontinue Lumigan treatment should be made taking into account the benefits of breastfeeding for a child and the benefits of treatment for a woman. Children. The efficacy and safety of Lumigan in children have not been studied, so the drug is not recommended for use in patients of this age category (under the age of 18). 

28 reviews for Lumigan

  1. Bobby Huffman

  2. Kenneth Roach

  3. Frances Wagner

  4. Albert Sullivan

  5. Kenneth Daniels

  6. Jason Garza

  7. Margaret Dawson

  8. Richard Vazquez

  9. Patricia Ruiz

  10. Eric Hess

  11. Richard Winters

  12. Judith Whitaker

  13. Stephanie Boyd

  14. Rachel Graham

  15. Jeffrey Fox

  16. Albert Wyatt

  17. Aaron Salinas

  18. Judy Mueller

  19. Julia Shelton

  20. Kelly Enriquez

  21. Charlotte Murray

  22. Carolyn Jenkins

  23. Raymond Wolfe

  24. Elijah Patrick

  25. Samuel Anderson

  26. Roger Delarosa

  27. Jeffrey Zimmerman

  28. Natalie Kelley

Add a review

Your email address will not be published. Required fields are marked *